Mark Cuban Pharmacy, Employer-Owned PBM Offer New ‘Supplemental Drug Discount Product’

Two newcomers in the pharmacy space are teaming up to offer what they describe as a “first-of-its-kind supplemental drug discount product” aimed at helping self-funded employers winnow down their drug costs. The product — EmsanaRx Plus — is the result of a collaboration between the Mark Cuban Cost Plus Drugs Company and EmsanaRx, a not-for-profit PBM owned by the Purchaser Business Group on Health (PBGH). Yet industry observers tell AIS Health, a division of MMIT, that they’re skeptical about how disruptive the new product will truly be.

“Whether EmsanaRx Plus, integrating Cost Plus Drugs, fills an unmet need in the market will depend on how Cost Plus Drugs is integrated into the self-insured employer’s benefit design,” suggests Elan Rubinstein, Pharm.D., principal at EB Rubinstein Associates.

© 2024 MMIT
Leslie Small

Leslie Small

Leslie has been working in journalism since 2009 and reporting on the health care industry since 2014. She has covered the many ups and downs of the Affordable Care Act exchanges, the failed health insurer mega-mergers, and hundreds of other storylines spanning subjects such as Medicaid managed care, Medicare Advantage, employer-sponsored insurance, and prescription drug coverage. As the managing editor of Health Plan Weekly and Radar on Drug Benefits, she writes and edits for both publications while overseeing a small team of reporters who also focus on the managed care sector. Before joining AIS Health, she was a senior editor for the e-newsletter Fierce Health Payer, and she started her career as a copy editor at multiple local newspapers. She graduated with a dual degree in journalism and political science from Penn State University.

Related Posts

October 13

Mark Cuban Cost Plus Drugs Strikes First Deals with Insurer, Outside PBM

Read More
February 3

Mark Cuban’s Cash Pharmacy Launches Amid Strong Competition

Read More


Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today